Schering-Plough - Biotech Market Share Report

Schering-Plough market share report graphic featuring Schering-Plough, Remicade and Peg-Intron logos. Company: Schering-Plough
2007 Sales: $2.5 billion
Market share: 3.4%
CAGR: 1.4%

What they have: Schering-Plough, which markets J&J's Remicade outside of the U.S, racked up $1.6 billion in sales in 2007. The company's pegylated interferon Hepatitis C injection Peg-Intron also brought in $911 million.

What to look for: Schering is partnered with J&J's Centocor on golimumab for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and ulcerative colitis. The company beefed up it's biotech pipeline with the $14 billion  acquisiton of Organon Biosicences last year.

Schering-Plough - Biotech Market Share Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.